Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids

Recent studies have shown that administering the aromatase inhibitor exemestane after 2–3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment. Although many of the adverse ef...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Francini, G, Petrioli, R, Montagnani, A, Cadirni, A, Campagna, S, Francini, E, Gonnelli, S
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2006
Предметы:
Clinical Study
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2360614/
https://ncbi.nlm.nih.gov/pubmed/16835585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603258
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы